FDA Clearance Tracker · P960011-S004
BIOLON 1% SODIUM HYALURONATE FOR OPHTHALMIC SURGERY
Last checked: Nov 20, 2026Latest source record: Mar 23, 2001 (this decision)Source: openFDAMethods & limitations
Decided
Mar 23, 2001
Approved
Time to decision
346 days
Received Apr 11, 2000. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P960011-S004
- Device name
- BIOLON 1% SODIUM HYALURONATE FOR OPHTHALMIC SURGERY
- Applicant
- Altacor , Ltd.
- Applicant location
- Theale
- Received
- Apr 11, 2000
- Decided
- Mar 23, 2001
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
- Original approval
- P960011
Device type
- Device type
- AID, SURGICAL, VISCOELASTIC (LZP)
- Device class
- Class III
- Regulation
- 21 CFR 886.4275
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR CIBA VISION TO MARKET BIOLON(TM) 1% SODIUM HYALURONATE FOR OPHTHALMIC SURGERY IN THE UNITED STATES UNDER THE TRADE NAME "UNIVISC".
Source documents
Other decisions for Altacor , Ltd.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.